A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses
- PMID: 23836036
A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses
Abstract
Influenza has long been considered a serious global health threat. The highly pathogenic avian influenza A virus (IAV) H5N1, particularly the currently identified IAV/H7N9 in humans in China, illustrates that influenza is still a significant public health problem. Due to the high mortality of H5N1, development of safe and effective vaccines against divergent strains of H5N1 influenza virus, especially the one capable of inducing both strong systemic and local immune responses in the vaccinated targets, is a challenge of immediate importance. In the present study, we designed two recombinant proteins containing highly conserved hemagglutinin (HA) residues 81-122 of H5N1 fused with Fc of human IgG (HA-81-122-Fc) and/or foldon (Fd) trimeric motif (HA-81-122-Fdc), and identified their immunogenicity in vaccinated mice. We found that HA-81-122-Fc and HA-81-122-Fdc proteins formed high molecular weight dimer and oligomer, respectively, and induced potent IgG antibodies in vaccinated mouse sera and lung wash. Stronger IgG1 (Th2-associated) and IgG2 (Th1-associated) antibody responses could be raised in the sera of mice following last vaccination of HA-81-122-Fdc than those raised by HA-81-122-Fc vaccination. Importantly, HA-81-122-Fdc is able to elicit high titers of IgA antibodies in vaccinated mouse lung wash and sera through the parenteral immunization pathway. Our data demonstrated that the recombinant protein containing highly conserved HA residues 81-122 of H5N1 fused with Fd and Fc could induce strong local mucosal and systemic humoral immune responses in the vaccinated animals, revealing the possibility of developing an effective Fc-mediated mucosal influenza vaccine.
Similar articles
-
Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.Hum Vaccin Immunother. 2015;11(12):2831-8. doi: 10.1080/21645515.2015.1074363. Hum Vaccin Immunother. 2015. PMID: 26260706 Free PMC article.
-
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10. Virology. 2008. PMID: 18786689
-
Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9. Antiviral Res. 2009. PMID: 19135483
-
Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.J Clin Virol. 2004 Dec;31 Suppl 1:S99-106. doi: 10.1016/j.jcv.2004.09.013. J Clin Virol. 2004. PMID: 15567101
-
A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.PLoS One. 2013;8(1):e53568. doi: 10.1371/journal.pone.0053568. Epub 2013 Jan 8. PLoS One. 2013. PMID: 23320093 Free PMC article.
Cited by
-
Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.J Med Virol. 2022 Sep;94(9):4265-4276. doi: 10.1002/jmv.27881. Epub 2022 Jun 1. J Med Virol. 2022. PMID: 35615895 Free PMC article.
-
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.Virology. 2016 Dec;499:375-382. doi: 10.1016/j.virol.2016.10.005. Epub 2016 Oct 15. Virology. 2016. PMID: 27750111 Free PMC article.
-
A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques.Front Plant Sci. 2022 Sep 28;13:901978. doi: 10.3389/fpls.2022.901978. eCollection 2022. Front Plant Sci. 2022. PMID: 36247553 Free PMC article.
-
Identification of Influenza A/H7N9 virus infection-related human genes based on shortest paths in a virus-human protein interaction network.Biomed Res Int. 2014;2014:239462. doi: 10.1155/2014/239462. Epub 2014 May 18. Biomed Res Int. 2014. PMID: 24955349 Free PMC article.
-
Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.Hum Vaccin Immunother. 2014;10(12):3649-58. doi: 10.4161/hv.36122. Hum Vaccin Immunother. 2014. PMID: 25483702 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous